I've compiled some SNPs which have proven association with COVID-19

[Sars-Cov-2][Strong Indicator of Outcome risk] Rs4343

Risk: AG, GG (~75% of population?) [Common in Europeans]

Safe: AA (~25% of population?) [Common in Asians, Africans]

Source: https://www.sciencedirect.com/science/article/pii/S0378111920306132?via%3Dihub

[Sars-Cov-2][Outcome risk] rs657152

Risk: AA (15.2% of population)

Safe: AC, CC (84.8% of population)

Reason: Increased risk of respiratory failure

Source: https://pubmed.ncbi.nlm.nih.gov/32558485/

[IL-6][Outcome risk] rs1800795

Risk: GG (76.6% of population)

Safe: CG (18.6% of population)

Good: CC (4.8% of population)

Reason: IL-6 levels play an important role in cytokine release syndrome. GG is associated with higher IL-6 levels. CC is associated with lower IL-6 levels. IL-6 has been found to be a good predictor of respiratory failure in COVID-19 patients.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027108/

Source: https://pubmed.ncbi.nlm.nih.gov/32234467/

[Sars-Cov-1][Outcome risk] rs4804803

Risk: AA (61% of population)

Safe: AG, GG (39% of population)

Reason: During the Sars-Cov-1 outbreak, it was found that those with genotype AG or GG were 2.5 times more likely to have lower LDH levels, which is associated with a better clinical outcome.

Source: https://www.sciencedirect.com/science/article/pii/S0198885910000789

[Sars-Cov-1][Infection risk] rs2430561

Risk: AA, AT (~75% of population?)

Safe: TT (~25% of population?)

Reason: During the Sars-Cov-1 outbreak, it was found that those with the A allele were 5 times more likely to be infected.

Source: https://pubmed.ncbi.nlm.nih.gov/16672072/

[Sars-Cov-2][Outcome risk] rs10490770 (Caucasisn only)

Risk: AG, GG (~15.5% of population?)

Safe: AA (~84.5% of population?)

Reason: Mirrors the result of the rs11385942 SNP in Caucasians. rs11385942 is not tracked for by popular DNA test companies.

Source: https://www.snpedia.com/index.php/Rs10490770

[Sars-Cov-2][Outcome risk] rs11385942

Risk: AA, A-

Safe: --

Reason: Associated with higher subspeciality to respiratory failure among COVID-19 patients.